Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Hoth Therapeutics, Inc. (HOTH)

4.8   -0.12 (-2.44%) 01-27 16:00
Open: 5 Pre. Close: 4.92
High: 5.16 Low: 4.78
Volume: 116,536 Market Cap: 7(M)

Technical analysis

as of: 2023-01-27 4:45:12 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 10.22     One year: 14.59
Support: Support1: 2.7    Support2: 2.25
Resistance: Resistance1: 8.75    Resistance2: 12.5
Pivot: 5.87
Moving Average: MA(5): 5.01     MA(20): 6.28
MA(100): 6.23     MA(250): 10.02
MACD: MACD(12,26): 0     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 2.9     %D(3): 3.4
RSI: RSI(14): 44.8
52-week: High: 40.75  Low: 0.37
Average Vol(K): 3-Month: 767 (K)  10-Days: 68 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HOTH ] has closed above bottom band by 14.8%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.17 - 5.2 5.2 - 5.23
Low: 4.7 - 4.73 4.73 - 4.77
Close: 4.74 - 4.8 4.8 - 4.85

Company Description

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Headline News

Wed, 25 Jan 2023
Hoth Therapeutics Picks Three Sites for Mid-Stage Trial in Skin Disorders in Cancer Patients -

Wed, 25 Jan 2023
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy - Yahoo Finance

Mon, 23 Jan 2023
How To Enjoy A Planet Hoth Winter In North Dakota & Minnesota - US 103.3

Mon, 23 Jan 2023
Lady Go-Hawks take first in Decorah, 5 girls finish 1st - Cedar Valley Daily Times

Fri, 20 Jan 2023
George Lucas Left A Lot Of Room For Interpretation When Writing ... - /Film

Tue, 17 Jan 2023
Doctor Aphra Once Saved the Rebels at Hoth - By Beating Darth ... - CBR - Comic Book Resources

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 1 (M)
Shares Float 1 (M)
% Held by Insiders 54.8 (%)
% Held by Institutions 8.3 (%)
Shares Short 22 (K)
Shares Short P.Month 34 (K)

Stock Financials

EPS -0.53
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.67
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -55
Return on Equity (ttm) -103.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -11 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -9.06
PEG Ratio 0
Price to Book value 0.71
Price to Sales 0
Price to Cash Flow -0.59

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.